These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35953567)

  • 1. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
    Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH
    Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.
    Latysheva A; Emblem KE; Brandal P; Vik-Mo EO; Pahnke J; Røysland K; Hald JK; Server A
    Neuroradiology; 2019 May; 61(5):545-555. PubMed ID: 30712139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of apparent diffusion coefficient in the grading of adult isocitrate dehydrogenase-mutant astrocytomas: relationship with the Ki-67 proliferation index.
    She Y; Liu X; Jiang J; Wang X; Niu Q; Zhou J
    Acta Radiol; 2024 May; 65(5):489-498. PubMed ID: 38644751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
    Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
    AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
    Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
    Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
    Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.
    Lin Y; Xing Z; She D; Yang X; Zheng Y; Xiao Z; Wang X; Cao D
    Neuroradiology; 2017 Jun; 59(6):555-562. PubMed ID: 28474187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
    Fujita Y; Nagashima H; Tanaka K; Hashiguchi M; Hirose T; Itoh T; Sasayama T
    World Neurosurg; 2021 May; 149():e253-e260. PubMed ID: 33610870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
    Santosh V; Rao S
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
    Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
    Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
    Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of molecular analysis in diffuse glioma stratification.
    Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
    Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
    Ammendola S; Broggi G; Barresi V
    Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
    Roux A; Tauziede-Espariat A; Zanello M; Peeters S; Zah-Bi G; Parraga E; Edjlali M; Lechapt E; Shor N; Bellu L; Berzero G; Dormont D; Dezamis E; Chretien F; Oppenheim C; Sanson M; Varlet P; Capelle L; Dhermain F; Pallud J
    Neuro Oncol; 2020 Jul; 22(7):993-1005. PubMed ID: 32025725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
    Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
    Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.